{"id":546098,"date":"2021-06-03T23:06:01","date_gmt":"2021-06-03T23:06:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=546098"},"modified":"2021-06-03T23:06:01","modified_gmt":"2021-06-03T23:06:01","slug":"hemophilia-b-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novo-nordisk-csl-behring-bioverativ-therapeutics-uniqure-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novo-nordisk-csl-behring-bioverativ-therapeutics-uniqure-and-others_546098.html","title":{"rendered":"Hemophilia B Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novo Nordisk, CSL Behring, Bioverativ Therapeutics, UniQure and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1622695033.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Hemophilia B Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novo Nordisk, CSL Behring, Bioverativ Therapeutics, UniQure and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1622695033.jpeg\" alt=\"Hemophilia B Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Novo Nordisk, CSL Behring, Bioverativ Therapeutics, UniQure and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Hemophilia B Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Hemophilia<\/strong> is defined as an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. It is caused by a gene defect that decides how factors VIII, IX, or XI are produced by the body. One of the Hemophilia type is Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, is a genetic disorder caused by missing or defective factor IX, a clotting protein. Although it is passed down from parents to children, about one-third of cases are caused by a spontaneous mutation, a change in a gene. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing.<\/p>\n<p style=\"text-align: justify;\">&#8220;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Hemophilia B Pipeline<\/a> Insight, 2020<\/strong>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Hemophilia B&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Hemophilia B&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Hemophilia B&nbsp;<\/strong>treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Hemophilia B companies covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Novo Nordisk<\/li>\n<li>CSL Behring<\/li>\n<li>Bioverativ Therapeutics<\/li>\n<li>UniQure<\/li>\n<li>Pfizer<\/li>\n<li>Freeline Therapeutics<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Hemophilia B Drugs<\/a> covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rebinyn<\/li>\n<li>Idelvion<\/li>\n<li>Alprolix<\/li>\n<li>Etranacogene dezaparvovec (AMT-061)<\/li>\n<li>Fidanacogene elaparvovec<\/li>\n<li>FLT180a<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Hemophilia B Report<\/strong><strong> Highlights:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Hemophilia B&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Hemophilia B&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Hemophilia B&nbsp;<\/strong><em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;<strong>Hemophilia B&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Hemophilia B<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Hemophilia B&nbsp;<\/p>\n<p style=\"text-align: justify;\">3. Hemophilia B&nbsp;Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4. Hemophilia B&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Hemophilia B Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Hemophilia B Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Hemophilia B Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Hemophilia B&nbsp;Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Hemophilia B&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Hemophilia B&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Hemophilia B&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Hemophilia B&nbsp;Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Hemophilia B&nbsp;Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC: https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;<\/strong><strong>DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=hemophilia-b-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novo-nordisk-csl-behring-bioverativ-therapeutics-uniqure-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=hemophilia-b-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novo-nordisk-csl-behring-bioverativ-therapeutics-uniqure-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hemophilia B Pipeline Hemophilia is defined as an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding as well as bleeding following injuries or surgery. It is caused by a gene defect &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-b-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-novo-nordisk-csl-behring-bioverativ-therapeutics-uniqure-and-others_546098.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-546098","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=546098"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/546098\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=546098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=546098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=546098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}